Please login to the form below

Not currently logged in

David Epstein joins Flagship Pioneering as executive partner

He most recently served as CEO of Novartis Pharmaceuticals

Flagship Pioneering David EpsteinUS-based Flagship Pioneering has appointed former Novartis Pharmaceuticals chief executive David Epstein as its executive partner.

In this newly-created position, Epstein will begin working with Rubius Therapeutics, a red blood cell-focused exploratory venture within the Flagship portfolio, as chairman of its board.

He brings over 25 years of drug development, commercialisation and leadership experience within the pharmaceuticals industry, most recently as chief executive officer of Novartis Pharmaceuticals.

Prior to taking up this lead role in 2010, Epstein founded Novartis Oncology and Novartis Molecular Diagnostics in 1989, leading the start-up businesses as president and chief executive officer.

Dr Noubar Afeyan, founder and chief executive of Flagship, said: “David is a leader and long-time pioneer within the pharma industry, having developed dozens of new medicines benefiting millions of patients around the world.

“His progressive approach to science and business acumen gleaned over his tenured career in the pharmaceutical industry complements Flagship's culture and team.

“We will apply his expertise broadly as we continue making and realising the maximum potential of disruptive innovations that yield unprecedented therapies.”

25th January 2017

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...